Research peptide head to head
CJC-1295 vs Sermorelin
Both are GHRH (growth-hormone-releasing hormone) analogues studied in preclinical literature. Sermorelin is the older, unmodified N-terminal fragment with a very short half-life. CJC-1295 is the newer tetra-substituted analogue, optionally bound to a DAC (Drug Affinity Complex) for albumin attachment that extends half-life dramatically. Neither has a UK marketing authorisation as a medicine. UK retailers sell both as research use only.
| CJC-1295 | Sermorelin | |
|---|---|---|
| Class | GHRH analogue | GHRH analogue |
| Amino acids | 30 (DAC variant 30 + DAC link) | 29 |
| Half-life | Approx 30 min (no DAC); 8+ days (with DAC) | Approx 10 to 20 minutes |
| Structural modification | Tetra-substituted, optional DAC for albumin binding | Unmodified N-terminal fragment of human GHRH |
| Discovery / origin | Conjuchem (mid-2000s) | Salk Institute (1970s); marketed as Geref by Serono |
| UK regulatory status | No marketing authorisation; research use only | No marketing authorisation; research use only |
| Often paired with | Ipamorelin | Ipamorelin |
| Typical CoA emphasis | DAC verification critical | Standard HPLC |
Cross-reference: Sermorelin encyclopedia · best UK Sermorelin retailers.
Ready to buy
Shop UK peptides, collagen and GLP-1 routes
Compare UK retailers, clinics and pharmacies across every PeptideClear category.